ACP
IMDZ

Acuta Capital Partners’s Immune Design Corp. IMDZ Stock Holding History

Acuta Capital Partners’s Portfolio IMDZ Stock Details IMDZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-274,100
Closed -$1.07M – 102
2017
Q4 		$1.07M Buy
+274,100
New +$1.49M 0.2% 56

Other funds holding IMDZ

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Acuta Capital Partners's IMDZ Position: Q1 2018 in Review

Acuta Capital Partners sold out of Immune Design Corp. (IMDZ) in Q1 2018, closing a stake of 274,100 shares — an estimated $1.07M sold.

Acuta Capital Partners first reported a position in IMDZ in Q4 2017 and held it in 1 quarter. The position peaked at $1.07M in Q4 2017. 72 funds tracked by Wall St. Rank hold IMDZ as of Q1 2018.

  • Acuta Capital Partners reported no remaining Immune Design Corp. position as of Q1 2018 after selling out during the quarter.
  • Acuta Capital Partners sold 274,100 Immune Design Corp. shares in Q1 2018, an estimated $1.07M.
  • Acuta Capital Partners first reported a position in Immune Design Corp. in Q4 2017 and held it in 1 quarter.
  • Acuta Capital Partners's Immune Design Corp. position peaked at $1.07M in Q4 2017.
  • 72 funds tracked by Wall St. Rank held Immune Design Corp. as of Q1 2018.

Based on Acuta Capital Partners's 13F filing for Q1 2018, filed 15 May 2018.